Human Cd19-Cd22 Targeted T Cells
Central Nervous System Lymphoma
Hrain Biotechnology Co., Ltd.Cell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
73 Active assets in the Central Nervous System Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BBB |
(+)-VINCRISTINE Ono Pharmaceutical Co., Ltd. | Phase 4 | BBB |
METHOTREXATE Assistance Publique Hopitaux De Marseille | Phase 4 | BB |
Orelabrutinib The First Affiliated Hospital with Nanjing Medical University | Phase 3 | BB |
Inno-206 Juan P. Alderuccio, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Human Cd19-Cd22 Targeted T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →